Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
Elon Musk’s Boring Company came under fire Tuesday during a more than three-hour Nevada legislative hearing about the Elon Musk-owned...
Shares of Waaree Energies, the country’s largest solar module manufacturer, have surged nearly 28% over the past two weeks, including...
The India–US trade deal marks a turning point for equities by removing a major source of tariff uncertainty, and lifting...
Amazon has more than 900 data centers spread across the planet. And if you ask Matt Garman, the CEO of...
Amazon MGM Studios reportedly spent $35 million marketing Melania: Twenty Days to History, a documentary following the first lady, with...
Shares of legal software firms and other data service companies plunged on Tuesday after Anthropic released a new AI automation...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
